Improving CAR T cell therapy for glioblastoma treatment
Official title: Optimizing CAR T therapy via metabolic engineering for thetreatment of GBM
Funded at Mayo Clinic Jacksonville · NIH-11239302 · Data updated 2026-11-12
This study is looking at ways to make CAR T cell therapy work better for people with glioblastoma by helping the CAR T cells get more nutrients they need to fight the tumor, and it will test these improved cells in mice to see if they can last longer and work more effectively against the cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project start | July 5, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $203,187 |
| NIH project number | 7R21CA282979-03 |
| Project ID | NIH-11239302 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are considering immunotherapy options.
✕Less likely to help
Patients with other types of cancer or those who do not have glioblastoma may not benefit from this research.
What this research studies
This research aims to enhance the effectiveness of CAR T cell therapy for glioblastoma (GBM) by addressing the competition for nutrients within the tumor microenvironment. The researchers hypothesize that by improving the metabolic fitness of CAR T cells, they can better compete with tumor cells for essential nutrients like glucose. The study will involve genetically modifying CAR T cells to increase their glucose uptake and testing these modified cells in mouse models of glioma. This innovative approach seeks to improve the persistence and function of CAR T cells in the challenging environment of GBM tumors.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR T cell therapies for patients with glioblastoma, potentially improving survival rates.
How similar studies have gone: While CAR T cell therapy has shown promise in other cancers, this specific approach targeting metabolic engineering in glioblastoma is novel and has not been extensively tested.
Where this research is happening
-
Mayo Clinic Jacksonville
Jacksonville, United States Active
Researchers
- Principal investigator: Deleyrolle, Loic Pierre — Mayo Clinic Jacksonville
- Study coordinator: Deleyrolle, Loic Pierre
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.